European Equities Traded in the US as American Depositary Receipts Rise Friday

MT Newswires Live
2024-10-18

European equities traded in the US as American depositary receipts were moving modestly higher late Friday morning, rising 0.3% to 1,407.78 on the S&P Europe Select ADR Index, but the gains will likely not be enough to keep the index from ending the week about 1.5% lower.

From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and 3D printer company Materialise (MTLS), which climbed 6.3% and 3.4% respectively. They were followed by furniture maker Natuzzi (NTZ) and pharmaceutical company Ascendis Pharma (ASND), which increased 2.4% and 1.7% respectively.

The decliners from continental Europe were led by biopharmaceutical company Genfit (GNFT) and biotech firm BioNTech (BNTX), which fell 6.4% and 4.3% respectively. They were followed by DBV Technologies (DBVT) and Evaxion Biotech (EVAX), which were down 3.7% and 0.5% respectively.

From the UK and Ireland, the gainers were led by insurance company Prudential (PUK) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which rose 3.4% and 3.2% respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Verona Pharma (VRNA), which were up 2.2% and 0.9% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and British American Tobacco (BTI), which dropped 5.1% and 2.7% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company TC Biopharm (TCBP), which lost 2% and 0.4% respectively.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10